The world health Organization recommends that the use of the isoniazid alone or in the combination with rifapentine to treat latent tuberculosis infections. The recent rise of drug-resistant tuberculosis infection has raised concerns about the resistibility of the disease in the maximum possible way. This was further complicated the issues and hence, the death rate concerned with this has increased up to 44 percent in the past days. Therefore, an attempt was made to evaluate the INH preventive therapy which was especially effective to calculate the effect of patients who have come in contact with multidrug-resistant tuberculosis. There have been many cohort studies that have been conducted so far in order to evaluate the causes of the drug rise. The patients were gathered in the number of 4587 and hence, the data regarding them was collected around September 2009, and hence, the process of data collection was continued till last year which was 2019. The results showcased that amongst the people who were studied extensively, nearly 50 percent were able to initiate the INH preventive therapy at enrollment. The protective effect of INH was more extreme in contacts exposed to drug-sensitive tuberculosis. The ratio of this was ranged between 0.18 to 0.48. In the second independent study, tuberculosis was able to occur in the median range of 15-20 percent. Therefore, there is a need of more research to be conducted in this regard.

Ref art: